Zuvaroz
Therapeutic Segment:
Anti-hyperlipidemic
Generic Name:
Rosuvastatin
Description:
Zuvaroz (Rosuvastatin), a synthetic lipid-lowering agent for oral administration. Rosuvastatin Calcium is bis[(E)-7-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsulfonyl) amino]pyrimidin-5 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt. The molecular formula for Rosuvastatin Calcium is (C22H27FN3O6S)2Ca.
Indication:
Zuvaroz (Rosuvastatin) is indicated for the treatment of:
- Hyperlipidemia and mixed Dislipidemia: As Adjunctive therapy to diet to reduce elevated Total-C, LDL-C ApoB, nonHDL-C and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.
- Pediatric Patients 10 to 17 years of age with Heterozygous Familal Hypercholesterolemia (HeFH): Adjunct to diet to reduce Total-C, LDL-C and ApoB levels in adolescent boys and girls, who are at least one year postmenarche, 10-17 years of age with heterozygous familial hyperchlosterolemia if after an adequate trial of diet theraphy the following findings are present: LDL-C greater than 190 mg/dL or greater than 160 mg/dL and there is a positive family history premature cardiovascular disease (CVD) or two or more other CVD risk factors.
- Â Hypertriglyceridemia: As Adjunctive theraphy to diet for the treatment of adult patients with hypertriglyceridemia.
- Â Primary Dysbetalipoproteinemia: (Type III Hyperlipoproteinemia) As as adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia.)
- Â Homozygous Familal Hypercholesterolemia: As Adjunctive theraphy to other lipid lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C. Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia.
- Slowing of the Progression of Atherosclerosis: As adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.
- Prevention of Cardiovascular Events: Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.
Formulation:
- TabletsÂ
Strength:
- 5mg
- 10mg
- 20mg
Pack Size:
- 14’s





